Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more
Relmada Therapeutics Inc (RLMD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.710x
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has a cash flow conversion efficiency ratio of -0.710x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.72 Million) by net assets ($9.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Relmada Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Relmada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Relmada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relmada Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Water Group Co Ltd
SHG:601158
|
0.035x |
|
Hollyland China Electronics Technology Corp Ltd
SHE:002729
|
0.037x |
|
Danhua Chemical Technology Co Ltd A
SHG:600844
|
0.043x |
|
EPIC Suisse AG
SW:EPIC
|
0.034x |
|
Galatasaray Sportif Sinai ve Ticari Yatirimlar AS
IS:GSRAY
|
-0.384x |
|
Shanghai Kai Kai Industry Co Ltd A
SHG:600272
|
0.033x |
|
Dave & Buster’s Entertainment
NASDAQ:PLAY
|
0.443x |
|
Ls Cable & System Asia Ltd
KO:229640
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Relmada Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Relmada Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.52 Million | $-51.76 Million | -1.457x | -140.74% |
| 2023-12-31 | $85.36 Million | $-51.66 Million | -0.605x | +18.12% |
| 2022-12-31 | $140.44 Million | $-103.80 Million | -0.739x | -67.55% |
| 2021-12-31 | $208.26 Million | $-91.87 Million | -0.441x | -67.49% |
| 2020-12-31 | $105.58 Million | $-27.81 Million | -0.263x | -251866.34% |
| 2019-12-31 | $115.68 Million | $-12.09K | 0.000x | -100.01% |
| 2018-12-31 | $-5.51 Million | $-6.00 Million | 1.089x | +124.59% |
| 2017-12-31 | $1.46 Million | $-6.47 Million | -4.428x | -137.26% |
| 2016-12-31 | $7.04 Million | $-13.14 Million | -1.866x | -1.33% |
| 2015-12-31 | $8.81 Million | $-16.23 Million | -1.842x | 0.00% |
| 2014-12-31 | $8.81 Million | $-16.23 Million | -1.842x | -191.19% |
| 2014-06-30 | $-1.11 Million | $-2.24 Million | 2.020x | +18788.61% |
| 2013-12-31 | $-1.11 Million | $-11.86K | 0.011x | +101.61% |
| 2012-12-31 | $11.36K | $-7.57K | -0.666x | -- |